Related Experiment Videos
Cell death regulation during multistep lymphomagenesis
B Hsu1, M C Marin, T J McDonnell
1Department of Molecular Pathology, University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA.
Abstract:
The three most common genetic abnormalities occurring in malignant lymphomas involve alterations resulting in the deregulated expression of the c-myc and bcl-2 oncogenes and the inactivation of the p53 tumor suppressor gene. Relevant strains of genetically engineered mice, including bcl-2-Ig and E mu-myc transgenic mice and p53 knockout mice, have been used to prospectively examine the regulation of apoptotic cell death by these genes, individually and in combination, and their contribution to in vivo lymphomagenesis. The potential importance of the therapeutic induction of apoptosis is discussed.
Insights
Genetic alterations in malignant lymphomas, including c-myc, bcl-2, and p53 genes, were studied in mice. These genes regulate apoptosis and contribute to lymphomagenesis, suggesting therapeutic potential.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Malignant lymphomas often involve genetic abnormalities affecting key oncogenes and tumor suppressors.
- Common genetic alterations include deregulated expression of c-myc and bcl-2 oncogenes and p53 tumor suppressor gene inactivation.
Purpose of the Study:
- To investigate the role of c-myc, bcl-2, and p53 in regulating apoptosis and lymphomagenesis.
- To examine the combined effects of these genetic alterations in vivo.
- To discuss the therapeutic implications of inducing apoptosis.
Main Methods:
- Utilized genetically engineered mouse models: bcl-2-Ig and E mu-myc transgenic mice, and p53 knockout mice.
- Prospectively analyzed the regulation of apoptotic cell death.
- Studied the contribution of genetic alterations to in vivo lymphomagenesis.
Main Results:
- Demonstrated the critical roles of c-myc, bcl-2, and p53 in controlling apoptosis.
- Showcased how combined genetic alterations accelerate lymphomagenesis in mice.
- Provided insights into the mechanisms of lymphoma development.
Conclusions:
- Genetic alterations in c-myc, bcl-2, and p53 are central to malignant lymphoma pathogenesis.
- Understanding these pathways is crucial for developing targeted therapies.
- Therapeutic induction of apoptosis holds promise for lymphoma treatment.